Welcome to our dedicated page for Koninklijke Phil news (Ticker: PHG), a resource for investors and traders seeking the latest updates and insights on Koninklijke Phil stock.
Koninklijke Philips N.V. reports health technology developments across Diagnosis & Treatment, Connected Care and Personal Health. News from Royal Philips commonly covers order intake and comparable sales trends; product launches and regulatory clearances for imaging, image-guided therapy and AI software; and governance actions from its Annual General Meeting. Recent product themes include CT platforms such as Rembra and Spectral CT Verida, interventional guidance tools such as DeviceGuide and IntraSight Plus, and the Bridge Plus Occlusion Balloon for lead extraction procedures.
The company’s updates also address hospital monitoring, informatics, ultrasound, oral health and personal-care lines. Coverage reflects Philips’ role as a Netherlands-based global health technology company with securities traded on NYSE under PHG and on Euronext Amsterdam under PHIA.
Royal Philips (NYSE: PHG) reported that shareholders approved all proposals at the Annual General Meeting on May 8, 2026. Resolutions included the appointment of John DeFord to the Supervisory Board, re-appointments of three supervisory members, and re-appointment of Roy Jakobs as President/CEO and Chairman.
Shareholders also discharged the Board of Management and Supervisory Board. Philips referenced its Annual Report 2025 for financial statements and provided links for dividend and board composition details.
Summary not available.
Royal Philips (NYSE: PHG) on April 23, 2026 launched the Bridge Plus Occlusion Balloon to help electrophysiology teams manage rare superior vena cava (SVC) tears during transvenous lead extraction. Bridge Plus deploys in under two minutes, can reduce blood loss by up to 90%, and maintains hemostasis for at least 30 minutes. The device builds on Bridge technology used in more than 50,000 U.S. procedures and is commercially available in the United States; broader international availability is expected later in 2026, pending registrations.
Philips (NYSE: PHG) received FDA 510(k) clearance on April 22, 2026 for its Rembra platform — Rembra CT, Rembra RT and Areta RT — enabling faster, higher-throughput CT imaging and integrated radiation therapy planning.
The platform features an 85 cm bore, next-generation 4DCT, an 85 cm extended field of view for treatment planning, and throughput claims up to 270 exams per day under test conditions.
Royal Philips (NYSE: PHG) received FDA 510(k) clearance on April 16, 2026 for the Philips Spectral CT Verida, the company’s AI-powered, detector-based spectral CT system. Verida combines always-on dual-layer detection with an AI deep-learning reconstruction (Spectral Precise Image), reconstructing 145 images/sec and producing full exams in under 30 seconds, enabling up to 270 exams per day. Indications include radiology, interventional radiology, cardiology, oncology, and low-dose lung cancer screening within established protocols. Certain features have use limitations (pediatric validation and treatment-planning-specific modes); Spectral Precise Image is supplemental to clinical judgment.
Philips (NYSE: PHG) announced that Carla Goulart Peron, MD, Chief Medical Officer at Philips, was appointed to the Board of Directors of the Medical Device Innovation Consortium (MDIC) on April 2, 2026.
The appointment links Philips’ medical leadership with MDIC’s regulatory science and device-evidence initiatives to support patient access to safe medical technologies.
Royal Philips (NYSE: PHG) received FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide, an AI-powered solution that provides real-time visualization and navigation during minimally invasive mitral transcatheter edge-to-edge repair (M-TEER).
DeviceGuide auto-tracks the Edwards PASCAL Ace device, integrates live 3D echo and X-ray via Azurion and EPIQ platforms, was developed with Edwards Lifesciences, and will be showcased at ACC 2026. Commercial availability is subject to market release and regional regulatory clearance.
Philips (NYSE:PHG) launched IntraSight Plus, an interventional cardiology platform cleared by the FDA 510(k) and CE marked for the USA and Europe. The system combines Class IA IVUS, iFR/FFR physiology, co-/tri-registration and real-time device visualization, and claims up to 47% system operation time savings. A first patient case occurred on March 19, 2026, enabling complete revascularization using integrated tri-registered imaging and physiology at the bedside. Commercial availability depends on market release and local regulatory requirements.
Royal Philips (NYSE: PHG) ranked No. 1 among medtech companies in the European Patent Office Technology Dashboard 2025 and remained the largest Dutch patent applicant with 1,289 European patent applications across domains and 676 Medtech filings in 2025. Philips invested > 9% of sales in R&D in 2025 and reported ~53,000 patent rights.
The company highlighted platform-based hardware, software, data and AI solutions and said its innovation improved the lives of 2 billion people in 2025, targeting 2.5 billion lives per year by 2030.
Royal Philips (NYSE: PHG) has convened its Annual General Meeting of Shareholders (AGM) 2026 and published the agenda with explanatory notes. The AGM is scheduled for Friday, May 8, 2026 at 10:00 CET at Hotel Okura Amsterdam.
Key items include the proposed appointment of John DeFord to the Supervisory Board; re-appointments of Paul Stoffels, Herna Verhagen, and Sanjay Poonen; and re-appointment of Roy Jakobs as President/CEO and Board of Management member, all effective May 8, 2026. The agenda also covers the 2025 Remuneration Report (advisory), a proposed Supervisory Board Remuneration Policy, adoption of financial statements, and dividend options.